PaulaJBusseMD
Allergy & Immunology • New York, NYAssistant Professor, Medicine, Icahn School of Medicine
Dr. Busse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 E 98th St
New York, NY 10029Phone+1 212-241-0764Fax+1 212-534-0971
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Allergy and Immunology, 1999 - 2001- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999
University of Rochester School of Medicine and DentistryClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
- Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
- Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents Start of enrollment: 2022 May 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 169 citationsB-cell epitopes as a screening instrument for persistent cow's milk allergy.K.M. Jarvinen, Kirsten Beyer, Leticia Vila, Pantipa Chatchatee, Paula J. Busse
The Journal of Allergy and Clinical Immunology. 2002-08-01 - 19 citationsACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.Shlomo A. Koyfman, Jay S. Cooper, Jonathan J. Beitler, Paul M. Busse, Christopher U. Jones
Head & Neck. 2016-02-01 - 21 citationsSafety of C1-Esterase Inhibitor in Acute and Prophylactic Therapy of Hereditary Angioedema: Findings from the Ongoing International Berinert Patient RegistryPaula J. Busse, Anette Bygum, Jonathan M. Edelman, William R. Lumry, Thomas Machnig
The Journal of Allergy and Clinical Immunology. in Practice. 2015-03-01
Journal Articles
- Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema AttacksJonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
Press Mentions
Interim Phase 4 Data Support TAKHZYRO® (Lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema PatientsFebruary 28th, 2022- $70m from NIAID to Establish Trial Site Network Focusing on Childhood Asthma in Low-Income Urban CommunitiesApril 26th, 2021
- Children’s National Hospital Becomes Part of the National CAUSE Clinical Research Network Under a $3 Million GrantApril 26th, 2021
- Join now to see all
Grant Support
- Contribution Of Tnf-Alpha To Mucus Cell Production In AsthmaNational Institute Of Allergy And Infectious Diseases2010
- C1 Esterase Inhibitor As Treatment And Prevention In Hereditary AngioedemaNational Center For Research Resources2009
- Contribution Of Tnf-Alpha To Mucus Cell Production In AsthmaNational Institute Of Allergy And Infectious Diseases2006–2009
- Change TrialNational Center For Research Resources2008
- Efficacy And Safety Of Purified C1 Esterase Inhibitor For Treatment Of HaeNational Center For Research Resources2006–2007
- An Ascending Four-Dose Placebo Controlled Study To Assess The Efficacy And To...National Center For Research Resources2004
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
